P1130: Acalabrutinib in treatment-naive or relapsed/refractory Waldenström macroglobulinemia: 5-year follow-up of a Phase 2, single-arm study

Simon Joseph	Rule

doi:10.1097/01.HS9.0000847388.33116.c7

P1130: Acalabrutinib in treatment-naive or relapsed/refractory Waldenström macroglobulinemia: 5-year follow-up of a Phase 2, single-arm study

Simon Joseph Rule

Peninsula Medical School

Research output: Contribution to journal › Article › peer-review

Original language	English
Journal	HemaSphere
Volume	6
Issue number	S3
DOIs	https://doi.org/10.1097/01.HS9.0000847388.33116.c7
Publication status	Published - 2022

Access to Document

10.1097/01.HS9.0000847388.33116.c7

Cite this

@article{388ffa2aeab645be8848909a1f794d7a,

title = "P1130: Acalabrutinib in treatment-naive or relapsed/refractory Waldenstr{\"o}m macroglobulinemia: 5-year follow-up of a Phase 2, single-arm study",

author = "\{Joseph Rule\}, Simon",

year = "2022",

doi = "10.1097/01.HS9.0000847388.33116.c7",

language = "English",

volume = "6",

journal = "HemaSphere",

issn = "2572-9241",

publisher = "John Wiley and Sons Inc.",

number = "S3",

}